Targeted therapy using nanotechnology: focus on cancer

References

• KimBYRutkaJTChanWCNanomedicineN Engl J Med2010363252434244321158659
   PubMed Web of Science ®Google Scholar
• PeerDKarpJMHongSFarokhzadOCMargalitRLangerRNanocarriers as an emerging platform for cancer therapyNat Nanotechnol200721275176018654426
   PubMed Web of Science ®Google Scholar
• ZhangLGuFXChanJMWangAZLangerRSFarokhzadOCNanoparticles in medicine: therapeutic applications and developmentsClin Pharmacol Ther200883576176917957183
   PubMed Web of Science ®Google Scholar
• RiehemannKSchneiderSWLugerTAGodinBFerrariMFuchsHNanomedicine – challenge and perspectivesAngew Chem Int Ed Engl200948587289719142939
   PubMed Web of Science ®Google Scholar
• DoaneTLBurdaCThe unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapyChem Soc Rev20124172885291122286540
   PubMed Web of Science ®Google Scholar
• FerrariMCancer nanotechnology: opportunities and challengesNat Rev Cancer20055316117115738981
   PubMed Web of Science ®Google Scholar
• DavisMEChenZGShinDMNanoparticle therapeutics: an emerging treatment modality for cancerNat Rev Drug Discov20087977178218758474
   PubMed Web of Science ®Google Scholar
• FarokhzadOCLangerRImpact of nanotechnology on drug deliveryACS Nano200931162019206243
   PubMed Web of Science ®Google Scholar
• PetrosRADeSimoneJMStrategies in the design of nanoparticles for therapeutic applicationsNat Rev Drug Discov20109861562720616808
   PubMed Web of Science ®Google Scholar
• LammersTKiesslingFHenninkWEStormGDrug targeting to tumors: principles, pitfalls and (pre-) clinical progressJ Control Release2012161217518721945285
   PubMed Web of Science ®Google Scholar
• JainKKRole of nanobiotechnology in the development of personalized medicineNanomedicine (Lond)20094324925219331532
   PubMed Web of Science ®Google Scholar
• ZhangXQXuXBertrandNPridgenESwamiAFarokhzadOCInteractions of nanomaterials and biological systems: Implications to personalized nanomedicineAdv Drug Deliv Rev201264131363138422917779
   PubMed Web of Science ®Google Scholar
• GindyMEPrud’hommeRKMultifunctional nanoparticles for imaging, delivery and targeting in cancer therapyExpert Opin Drug Deliv20096886587819637974
   PubMed Web of Science ®Google Scholar
• JanibSMMosesASMacKayJAImaging and drug delivery using theranostic nanoparticlesAdv Drug Deliv Rev201062111052106320709124
   PubMed Web of Science ®Google Scholar
• LammersTKiesslingFHenninkWEStormGNanotheranostics and image-guided drug delivery: current concepts and future directionsMol Pharm2010761899191220822168
   PubMed Web of Science ®Google Scholar
• Fernandez-FernandezAManchandaRMcGoronAJTheranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platformsAppl Biochem Biotechnol20111657–81628165121947761
   PubMed Web of Science ®Google Scholar
• YooDLeeAHShinTHCheonJTheranostic magnetic nanoparticlesAcc Chem Res2011441086387421823593
   PubMed Web of Science ®Google Scholar
• LeeDEKooHSunICRyuAHKimKKwonICMultifunctional nanoparticles for multimodal imaging and theragnosisChem Soc Rev20124172656267222189429
   PubMed Web of Science ®Google Scholar
• BaeKHChungHJParkTGNanomaterials for cancer therapy and imagingMol Cells201131429530221360197
   PubMed Web of Science ®Google Scholar
• TaylorAWilsonKMMurrayPFernigDGLevyRLong-term tracking of cells using inorganic nanoparticles as contrast agents: are we there yet?Chem Soc Rev20124172707271722362426
   PubMed Web of Science ®Google Scholar
• Villalonga-BarberCMicha-ScrettasMSteeleBRGeorgopoulosADemetzosCDendrimers as biopharmaceuticals: synthesis and propertiesCurr Top Med Chem20088141294130918855710
   PubMed Web of Science ®Google Scholar
• CliftMJStoneVQuantum dots: an insight and perspective of their biological interaction and how this relates to their relevance for clinical useTheranostics20122766868022896769
   PubMed Web of Science ®Google Scholar
• YamashitaTYamashitaKNabeshiHCarbon nanomaterials: efficacy and safety for nanomedicineMaterials201252350363
   PubMed Web of Science ®Google Scholar
• ParthaRConyersJLBiomedical applications of functionalized fullerene-based nanomaterialsInt J Nanomedicine2009426127520011243
   PubMed Web of Science ®Google Scholar
• KaurRBadeaINanodiamonds as novel nanomaterials for biomedical applications: drug delivery and imaging systemsInt J Nanomedicine2013820322023326195
   PubMed Web of Science ®Google Scholar
• KlumppCKostarelosKPratoMBiancoAFunctionalized carbon nanotubes as emerging nanovectors for the delivery of therapeuticsBiochim Biophys Acta20061758340441216307724
   PubMed Web of Science ®Google Scholar
• ZhuSXuGSingle-walled carbon nanohorns and their applicationsNanoscale20102122538254920957266
   PubMed Web of Science ®Google Scholar
• SperlingRARivera-GilPZhangFZanellaMParakWJBiological applications of gold nanoparticlesChem Soc Rev20083791896190818762838
   PubMed Web of Science ®Google Scholar
• CaiWGaoTHongHSunJApplications of gold nanoparticles in cancer nanotechnologyNanotechnol Sci Appl20081173224198458
   PubMedGoogle Scholar
• LalSClareSEHalasNJNanoshell-enabled photothermal cancer therapy: impending clinical impactAcc Chem Res200841121842185119053240
   PubMed Web of Science ®Google Scholar
• GiljohannDASeferosDSDanielWLMassichMDPatelPCMirkinCAGold nanoparticles for biology and medicineAngew Chem Int Ed Engl201049193280329420401880
   PubMed Web of Science ®Google Scholar
• DreadenECAlkilanyAMHuangXMurphyCJEl-SayedMAThe golden age: gold nanoparticles for biomedicineChem Soc Rev20124172740277922109657
   PubMed Web of Science ®Google Scholar
• BanghamADStandishMMWatkinsJCDiffusion of univalent ions across the lamellae of swollen phospholipidsJ Mol Biol19651312382525859039
   PubMed Web of Science ®Google Scholar
• TorchilinVPRecent advances with liposomes as pharmaceutical carriersNat Rev Drug Discov20054214516015688077
   PubMed Web of Science ®Google Scholar
• AllenTMCullisPRDrug delivery systems: entering the mainstreamScience200430356651818182215031496
   PubMed Web of Science ®Google Scholar
• LangerRFolkmanJPolymers for the sustained release of proteins and other macromoleculesNature19762635580797800995197
   PubMed Web of Science ®Google Scholar
• GrefRMinamitakeYPeracchiaMTTrubetskoyVTorchilinVLangerRBiodegradable long-circulating polymeric nanospheresScience19942635153160016038128245
   PubMed Web of Science ®Google Scholar
• LangerRDrug delivery and targetingNature1998392Suppl 66795109579855
   PubMed Web of Science ®Google Scholar
• AlexisFPridgenEMLangerRFarokhzadOCNanoparticle technologies for cancer therapyHandb Exp Pharmacol2010197558620217526
   PubMedGoogle Scholar
• ShiJXiaoZKamalyNFarokhzadOCSelf-assembled targeted nanoparticles: evolution of technologies and bench to bedside translationAcc Chem Res201144101123113421692448
   PubMed Web of Science ®Google Scholar
• WalkeyCDChanWCUnderstanding and controlling the interaction of nanomaterials with proteins in a physiological environmentChem Soc Rev20124172780279922086677
   PubMed Web of Science ®Google Scholar
• AlexisFPridgenEMolnarLKFarokhzadOCFactors affecting the clearance and biodistribution of polymeric nanoparticlesMol Pharm20085450551518672949
   PubMed Web of Science ®Google Scholar
• OtsukaHNagasakiYKataokaKPEGylated nanoparticles for biological and pharmaceutical applicationsAdv Drug Deliv Rev200355340341912628324
   PubMed Web of Science ®Google Scholar
• AvgoustakisKPegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug deliveryCurr Drug Deliv20041432133316305394
   PubMedGoogle Scholar
• BetancourtTByrneJDSunaryoNPEGylation strategies for active targeting of PLA/PLGA nanoparticlesJ Biomed Mater Res A200991126327618980197
   PubMedGoogle Scholar
• JokerstJVLobovkinaTZareRNGambhirSSNanoparticle PEGylation for imaging and therapyNanomedicine (Lond)20116471572821718180
   PubMed Web of Science ®Google Scholar
• KnopKHoogenboomRFischerDSchubertUSPoly(ethylene glycol) in drug delivery: pros and cons as well as potential alternativesAngew Chem Int Ed Engl201049366288630820648499
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAThe hallmarks of cancerCell20001001577010647931
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• GabizonAShmeedaHBarenholzYPharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studiesClin Pharmacokinet200342541943612739982
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationDrugs Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfmAccessed November 5, 2013
   Google Scholar
• HuynhNTPassiraniCSaulnierPBenoitJPLipid nanocapsules: a new platform for nanomedicineInt J Pharm2009379220120919409468
   PubMed Web of Science ®Google Scholar
• GradisharWJTjulandinSDavidsonNPhase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerJ Clin Oncol200523317794780316172456
   PubMed Web of Science ®Google Scholar
• MontanaMDucrosCVerhaeghePTermeTVanellePRathelotPAlbumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancersJ Chemother2011232596621571619
   PubMed Web of Science ®Google Scholar
• MakadiaHKSiegelSJPoly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrierPolymers (Basel)2011331377139722577513
   PubMed Web of Science ®Google Scholar
• ElsabahyMWooleyKLDesign of polymeric nanoparticles for biomedical delivery applicationsChem Soc Rev20124172545256122334259
   PubMed Web of Science ®Google Scholar
• NicolasJMuraSBrambillaDMackiewiczNCouvreurPDesign, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug deliveryChem Soc Rev20134231147123523238558
   PubMed Web of Science ®Google Scholar
• KamalyNXiaoZValenciaPMRadovic-MorenoAFFarokhzadOCTargeted polymeric therapeutic nanoparticles: design, development and clinical translationChem Soc Rev20124172971301022388185
   PubMed Web of Science ®Google Scholar
• StrebhardtKUllrichAPaul Ehrlich’s magic bullet concept: 100 years of progressNat Rev Cancer20088647348018469827
   PubMed Web of Science ®Google Scholar
• CollinsIWorkmanPNew approaches to molecular cancer therapeuticsNat Chem Biol200621268970017108987
   PubMed Web of Science ®Google Scholar
• MatsumuraYMaedaHA new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancsCancer Res19864612 Pt 1638763922946403
   PubMed Web of Science ®Google Scholar
• MaedaHWuJSawaTMatsumuraYHoriKTumor vascular permeability and the EPR effect in macromolecular therapeutics: a reviewJ Control Release2000651–227128410699287
   PubMed Web of Science ®Google Scholar
• CarmelietPJainRKAngiogenesis in cancer and other diseasesNature2000407680124925711001068
   PubMed Web of Science ®Google Scholar
• DanquahMKZhangXAMahatoRIExtravasation of polymeric nanomedicines across tumor vasculatureAdv Drug Deliv Rev201163862363921144874
   PubMed Web of Science ®Google Scholar
• JainRKDelivery of molecular and cellular medicine to solid tumorsAdv Drug Deliv Rev2001461–314916811259838
   PubMed Web of Science ®Google Scholar
• JainRKStylianopoulosTDelivering nanomedicine to solid tumorsNat Rev Clin Oncol201071165366420838415
   PubMed Web of Science ®Google Scholar
• HatakeyamaHAkitaHHarashimaHA multifunctional envelope type nanodevice (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemmaAdv Drug Deliv Rev201163315216020840859
   PubMed Web of Science ®Google Scholar
• ValleJWArmstrongANewmanCA phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junctionInvest New Drugs20112951029103720179989
   PubMed Web of Science ®Google Scholar
• MatsumuraYHamaguchiTUraTPhase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicinBr J Cancer200491101775178115477860
   PubMed Web of Science ®Google Scholar
• TongRChengJAnticancer polymeric nanomedicinesPolym Rev (Phila Pa)2007473345381
   Web of Science ®Google Scholar
• SingerJWPaclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxaneJ Control Release20051091–312012616297482
   PubMed Web of Science ®Google Scholar
• YoungCSchluepTHwangJEliasofSCRLX101 (formerly IT-101)-a novel nanopharmaceutical of camptothecin in clinical developmentCurr Bioact Compd20117181422081768
   PubMedGoogle Scholar
• Clinical Trials.govStudy of paclitaxel in patients with ovarian cancer Available from: http://clinicaltrials.gov/ct2/show/results/NCT00989131Accessed November 5, 2013
   Google Scholar
• TagamiTErnstingMJLiSDEfficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicinJ Control Release2011152230330921338635
   PubMed Web of Science ®Google Scholar
• SeetharamuNKimEHochsterHMartinFMuggiaFPhase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancerAnticancer Res201030254154520332467
   PubMed Web of Science ®Google Scholar
• Clinical Trials.govA Phase I trial of nanoliposomal CPT-11 (NL CPT-11) in patients with recurrent high-grade gliomas Available from: http://clinicaltrials.gov/show/NCT00734682Accessed November 5, 2013
   Google Scholar
• TardiPJohnstoneSHarasymNIn vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacyLeuk Res200933112913918676016
   PubMed Web of Science ®Google Scholar
• ByrneJDBetancourtTBrannon-PeppasLActive targeting schemes for nanoparticle systems in cancer therapeuticsAdv Drug Deliv Rev200860151615162618840489
   PubMed Web of Science ®Google Scholar
• AllenTMLigand-targeted therapeutics in anticancer therapyNat Rev Cancer200221075076312360278
   PubMed Web of Science ®Google Scholar
• CantonIBattagliaGEndocytosis at the nanoscaleChem Soc Rev20124172718273922389111
   PubMed Web of Science ®Google Scholar
• ArapWPasqualiniRRuoslahtiECancer treatment by targeted drug delivery to tumor vasculature in a mouse modelScience199827953493773809430587
   PubMed Web of Science ®Google Scholar
• MitraAMulhollandJNanAMcNeillEGhandehariHLineBRTargeting tumor angiogenic vasculature using polymer-RGD conjugatesJ Control Release2005102119120115653145
   PubMed Web of Science ®Google Scholar
• OerlemansCBultWBosMStormGNijsenJFHenninkWEPolymeric micelles in anticancer therapy: targeting, imaging and triggered releasePharm Res201027122569258920725771
   PubMed Web of Science ®Google Scholar
• DeckersRMoonenCTUltrasound triggered, image guided, local drug deliveryJ Control Release20101481253320709123
   PubMed Web of Science ®Google Scholar
• GuFLangerRFarokhzadOCFormulation/preparation of functionalized nanoparticles for in vivo targeted drug deliveryMethods Mol Biol200954458959819488725
   PubMedGoogle Scholar
• FarokhzadOCChengJTeplyBATargeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivoProc Natl Acad Sci U S A2006103166315632016606824
   PubMed Web of Science ®Google Scholar
• GuFZhangLTeplyBAPrecise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymersProc Natl Acad Sci U S A200810572586259118272481
   PubMed Web of Science ®Google Scholar
• YuBTaiHCXueWLeeLJLeeRJReceptor-targeted nanocarriers for therapeutic delivery to cancerMol Membr Biol201027728629821028937
   PubMed Web of Science ®Google Scholar
• SchramaDReisfeldRABeckerJCAntibody targeted drugs as cancer therapeuticsNat Rev Drug Discov20065214715916424916
   PubMed Web of Science ®Google Scholar
• ChamesPVan RegenmortelMWeissEBatyDTherapeutic antibodies: successes, limitations and hopes for the futureBr J Pharmacol2009157222023319459844
   PubMed Web of Science ®Google Scholar
• NobsLBucheggerFGurnyRAllemannEBiodegradable nanoparticles for direct or two-step tumor immunotargetingBioconjug Chem200617113914516417262
   PubMed Web of Science ®Google Scholar
• WeinerLMAdamsGPNew approaches to antibody therapyOncogene200019536144615111156528
   PubMed Web of Science ®Google Scholar
• EllingtonADSzostakJWIn vitro selection of RNA molecules that bind specific ligandsNature199034662878188221697402
   PubMed Web of Science ®Google Scholar
• TuerkCGoldLSystematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymeraseScience199024949685055102200121
   PubMed Web of Science ®Google Scholar
• KeefeADPaiSEllingtonAAptamers as therapeuticsNat Rev Drug Discov20109753755020592747
   PubMed Web of Science ®Google Scholar
• XiaoZFarokhzadOCAptamer-functionalized nanoparticles for medical applications: challenges and opportunitiesACS Nano2012653670367622574989
   PubMed Web of Science ®Google Scholar
• DanielsDAChenHHickeBJSwiderekKMGoldLA tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichmentProc Natl Acad Sci U S A200310026154161542114676325
   PubMed Web of Science ®Google Scholar
• FarokhzadOCJonSKhademhosseiniATranTNLavanDALangerRNanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cellsCancer Res200464217668767215520166
   PubMed Web of Science ®Google Scholar
• ChengJTeplyBASherifiIFormulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug deliveryBiomaterials200728586987617055572
   PubMed Web of Science ®Google Scholar
• ChangSSO’KeefeDSBacichDJReuterVEHestonWDGaudinPBProstate-specific membrane antigen is produced in tumor-associated neovasculatureClin Cancer Res19995102674268110537328
   PubMed Web of Science ®Google Scholar
• GhoshAHestonWDTumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancerJ Cell Biochem200491352853914755683
   PubMed Web of Science ®Google Scholar
• SchulkeNVarlamovaOADonovanGPThe homodimer of prostate-specific membrane antigen is a functional target for cancer therapyProc Natl Acad Sci U S A200310022125901259514583590
   PubMed Web of Science ®Google Scholar
• ChouLYMingKChanWCStrategies for the intracellular delivery of nanoparticlesChem Soc Rev201140123324520886124
   PubMed Web of Science ®Google Scholar
• ChoiCHAlabiCAWebsterPDavisMEMechanism of active targeting in solid tumors with transferrin-containing gold nanoparticlesProc Natl Acad Sci U S A201010731235124020080552
   PubMed Web of Science ®Google Scholar
• BrissetteRPrendergastJKGoldsteinNIIdentification of cancer targets and therapeutics using phage displayCurr Opin Drug Discov Devel200693363369
   PubMedGoogle Scholar
• SugaharaKNTeesaluTKarmaliPPCoadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugsScience201032859811031103520378772
   PubMed Web of Science ®Google Scholar
• ChanJMZhangLTongRSpatiotemporal controlled delivery of nanoparticles to injured vasculatureProc Natl Acad Sci U S A201010752213221820133865
   PubMed Web of Science ®Google Scholar
• TalekarMKendallJDennyWGargSTargeting of nanoparticles in cancer: drug delivery and diagnosticsAnticancer Drugs2011221094996221970851
   PubMed Web of Science ®Google Scholar
• LuYLowPSFolate-mediated delivery of macromolecular anticancer therapeutic agentsAdv Drug Deliv Rev200254567569312204598
   PubMed Web of Science ®Google Scholar
• LiangCYangYLingYHuangYLiTLiXImproved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinomaBioorg Med Chem201119134057406621641806
   PubMed Web of Science ®Google Scholar
• MarescaKPHillierSMFemiaFJA series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancerJ Med Chem200952234735719111054
   PubMed Web of Science ®Google Scholar
• ByunYMeaseRCLupoldSEPomperMGRecent development of diagnostic and therapeutic agents targeting glutamate carboxypeptidase II (GCPII)SupuranCTWinumJYDrug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease ApplicationsNew York, NYBinghe Wang Wiley Series in Drug Discovery and Development2009
   Google Scholar
• ZhouJNealeJHPomperMGKozikowskiAPNAAG peptidase inhibitors and their potential for diagnosis and therapyNat Rev Drug Discov20054121015102616341066
   PubMed Web of Science ®Google Scholar
• SannaVPintusGRoggioAMTargeted biocompatible nanoparticles for the delivery of (−)-epigallocatechin 3-gallate to prostate cancer cellsJ Med Chem20115451321133221306166
   PubMed Web of Science ®Google Scholar
• ChandranSSBanerjeeSRMeaseRCPomperMGDenmeadeSRCharacterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA)Cancer Biol Ther20087697498218698158
   PubMed Web of Science ®Google Scholar
• HrkachJVon HoffDMukkaram AliMPreclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profileSci Transl Med20124128128ra139
   Web of Science ®Google Scholar
• WijagkanalanWKawakamiSHashidaMGlycosylated carriers for cell-selective and nuclear delivery of nucleic acidsFront Biosci (Landmark Ed)2011162970298721622215
   PubMed Web of Science ®Google Scholar
• HashidaMNishikawaMYamashitaFTakakuraYCell-specific delivery of genes with glycosylated carriersAdv Drug Deliv Rev200152318719611718943
   PubMed Web of Science ®Google Scholar
• MatsumuraYGotohMMuroKPhase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancerAnn Oncol200415351752514998859
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govSafety study of infusion of SGT-53 to treat solid tumors Available from: http://clinicaltrials.gov/show/NCT00470613Accessed November 5, 2013
   Google Scholar
• ClinicalTrials.govStudy of MBP-426 in patients with second line gastric, gastroesophageal, or esophageal adenocarcinoma Available from: http://clinicaltrials.gov/show/NCT00964080Accessed November 5, 2013
   Google Scholar
• SankhalaKKMitaACAdininRA phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatinJ Clin Oncol200927S2535
   Web of Science ®Google Scholar
• ClinicalTrials.govSafety study of CALAA-01 to treat solid tumor cancers Available from: http://clinicaltrials.gov/show/NCT00689065Accessed November 5, 2013
   Google Scholar
• DavisMEThe first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinicMol Pharm20096365966819267452
   PubMed Web of Science ®Google Scholar
• TrialsUnitedA Phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors Available from: http://www.trialsunited.com/studies/NCT01702129
   Google Scholar
• MamotCRitschardRVogelBA phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumorsJ Clin Oncol20112915S3029
   Google Scholar
• GelmonKThe taxoids: paclitaxel and docetaxelLancet19943448932126712727967989
   PubMed Web of Science ®Google Scholar
• MonteroAFossellaFHortobagyiGValeroVDocetaxel for treatment of solid tumours: a systematic review of clinical dataLancet Oncol20056422923915811618
   PubMed Web of Science ®Google Scholar
• ZhangLZhangNHow nanotechnology can enhance docetaxel therapyInt J Nanomedicine201382927294123950643
   PubMed Web of Science ®Google Scholar
• GrefRLuckMQuellecP‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorptionColloids Surf B Biointerfaces2000183–430131310915952
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govA study of BIND-014 given to patients with advanced or metastatic cancer Available from: http://clinicaltrials.gov/show/NCT01300533Accessed November 5, 2013
   Google Scholar
• BakerJAjaniJScotteFDocetaxel-related side effects and their managementEur J Oncol Nurs2009131495919201649
   PubMed Web of Science ®Google Scholar
• Von HoffDDMitaMEisenbergPA Phase 1study of BIND-014, a PSMA-targeted nanoparticle containing docetaxel, in patients with refractory solid tumorsAbstract LB-203 presented at the annual meeting of the American Association for Cancer ResearchApril 6–10, 2013Washington, DC, USA
   Google Scholar
• ClinicalTrials.govA Phase 2 study to determine the safety and efficacy of BIND-014 (docetaxel nanoparticles injectable suspension) as second line therapy to patients with non-small cell lung cancer Available from: http://clinicaltrials.gov/show/NCT01792479Accessed November 5, 2013
   Google Scholar
• ClinicalTrials.govA Phase 2 study to determine the safety and efficacy of BIND-014 (docetaxel nanoparticles injectable suspension), administered to patients with metastatic castration-resistant prostate cancer Available from: http://clinicaltrials.gov/show/NCT01812746Accessed November 5, 2013
   Google Scholar